Overview
Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures
Status:
Completed
Completed
Trial end date:
2016-05-10
2016-05-10
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
The purpose of this study is to assess the safety and efficacy of intranasally-administrated fentanyl pectin spray (Lazanda®)given to decrease the pain during cystoscopy (the passage of a telescopic instrument into the bladder for purpose of diagnosing the cause of blood in the urine, urinary complaints or any other problems with the urinary bladder). The current standard practice is to use Lidocaine jelly (a local anesthetic) given through the urethra to lubricate and decrease local pain. In this study, an additional medicine (Lazanda®) is used to reduce pain that occurs during and after the above procedure.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Richard C Reznichek, MDCollaborator:
DepomedTreatments:
Fentanyl
Pectin
Criteria
Inclusion Criteria:1. Male adult patients scheduled for cystoscopy; additional procedures (e.g. ureteral stent
placement, stent exchange, bladder biopsy, retrograde pyelogram) may be included.
Exclusion Criteria:
1. History of analgesic abuse or opioid tolerance
2. Allergy to fentanyl or to any of the components of Lazanda®
3. Acute/chronic nasal problems such as rhinitis or sinusitis
4. Acute bronchial asthma / upper airway obstruction
5. Presence of bradycardia or history of seizures
6. Concomitant use of drugs that inhibit cytochrome P450 isoenzyme 3A4 (e.g., ritonavir,
ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone,
amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, monoamine
oxidase inhibitors and verapamil) or exposure to these drugs 30 days prior to
placement on the study.
7. Concomitant use of vasoconstrictive nasal decongestants (e.g., oxymetazoline,
phenylephrine, xylometazoline)
8. Numeric Rating Scale (NRS) pain score more than 0 at baseline
9. Any situation or condition which, in the investigator's opinion, puts the subject at
significant risk, or could confound the study results.